Breaking News

Moderna Gets $483M BARDA Deal for COVID-19 Vaccine

Award will fund manufacturing process scale-up to enable large-scale production in 2020 for pandemic response

By: Contract Pharma

Contract Pharma Staff

Moderna, a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, has entered an agreement for a commitment of up to $483 million from the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), to accelerate development of the company’s mRNA vaccine candidate (mRNA-1273) against the novel coronavi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters